SynthesisAdvances in therapy2025
The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis.
Synthesis in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic efficacy of leuprorelin acetate combined with rhGH in girls with ICPP and Its impact on body height and secondary sexual characteristics.Pakistan journal of medical sciences · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCompared to the well-established leuprolide acetate (LA) 1-month formulations, the LA 11.25 mg 3-month formulation could reduce the frequency of injections and potentially improve treatment adherence in children with central precocious puberty (CPP). The objective of this study was to evaluate the efficacy and safety of the LA 11.25 mg 3-month formulation in children with CPP.
methodsPubMed, Embase, WanFang, CNKI, Cochrane and clinical trial registries were searched from inception to 11 December 2023. Clinical trials reporting the efficacy and toxicity of the LA 11.25 mg 3-month formulation in children with CPP were considered. Efficacy endpoints included mean basal/stimulated or peak luteinizing hormone (LH) or follicle stimulating hormone (FSH), proportion of children with suppressed LH and FSH response, oestradiol and testosterone levels, bone age to chronological age (BA-CA) ratio, growth velocity before and after treatment and safety.
resultsTwelve articles with 657 CPP patients were included. Post-treatment, the mean stimulated LH levels decreased to 1.90 IU/l and 0.70 IU/l at 3 and 6 months, respectively, from the baseline value; 94% (< 3 IU/l) showed peak LH suppression at 6 months. Compared to baseline, the mean change in bone age to chronological age ratio decreased at 6, 12 months and 3 years by - 0.04, - 0.30 and - 1.10, respectively. Growth velocity was 6.11 cm/year at 6 months, decreased to 3.60 cm/year at 12 months and remained low at 2 (5.10 cm/year) and 3.5 years (5.30 cm/year), respectively. LA 11.25 mg 3 M formulation was well tolerated with most adverse events of local pain and erythaema being mild to moderate.
conclusionLA 11.25 mg 3-month formulation is efficacious in suppressing LH, FSH peak and other gonadal hormones and slowing the bone age and growth velocity in children with CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.